Activated T-cell and bispecific antibody immunotherapy for high-risk breast cancer - Bench to bedside

被引:18
作者
Lum, LG
Sen, M
机构
[1] Roger Williams Canc Med Ctr, Providence, RI USA
[2] Blood Ctr SE Wisconsin Inc, Milwaukee, WI 53233 USA
关键词
activated T cells; bispecific antibodies; stem cell transplant; immunotherapy;
D O I
10.1159/000046554
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Nontoxic approaches are needed to improve overall survival (OS) and progression-free survival (PFS) for highrisk breast cancer. Combination immunotherapy (IT) consisting of activated T cells (ATC), interleukin-2 (IL-2), and CTL (GM-CSF) was given after peripheral blood stem cell transplant (PBSCT). There were no major toxicities and there appear to be improvements in OS and PFS over historical controls. In order to develop specific cytotoxic T lymphocytes (CTL), we combined ATC with the use of bispecific antibody (BiAb). By arming ATC with anti-CD3 x anti-HER2/neu BiAb (HER2BiAb), the approach converts nonspecific ATC into HER2/neu (HER2) specific CTL. ATC remain armed, kill tumor targets for days, and produce cytokines after binding to tumor. Arming ATC with BiAbs may prove to be effective for targeting a variety of tumors with and without high-dose chemotherapy. Copyright (C) 2001 S. Karger AG, Basel.
引用
收藏
页码:130 / 136
页数:7
相关论文
共 30 条
[1]  
ANDERSON PM, 1989, J IMMUNOL, V142, P1383
[2]  
ANDERSON PM, 1988, CANCER IMMUNOL IMMUN, V27, P82
[3]  
CARTER CL, 1989, CANCER-AM CANCER SOC, V63, P181, DOI 10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO
[4]  
2-H
[5]   Phase I trial of anti-CD3-stimulated CD4+ T cells infusional interleukin-2, and cyclophosphamide in patients with advanced cancer [J].
Curti, BD ;
Ochoa, AC ;
Powers, GC ;
Kopp, WC ;
Alvord, WG ;
Janik, JE ;
Gause, BL ;
Dunn, B ;
Kopreski, MS ;
Fenton, R ;
Zea, A ;
Dansky-Ullmann, C ;
Strobl, S ;
Harvey, L ;
Nelson, E ;
Sznol, M ;
Longo, DL .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (08) :2752-2760
[6]   TREATMENT OF CANCER-PATIENTS WITH EXVIVO ANTI-CD3-ACTIVATED KILLER-CELLS AND INTERLEUKIN-2 [J].
CURTI, BD ;
LONGO, DL ;
OCHOA, AC ;
CONLON, KC ;
SMITH, JW ;
ALVORD, WG ;
CREEKMORE, SP ;
FENTON, RG ;
GAUSE, BL ;
HOLMLUND, J ;
JANIK, JE ;
OCHOA, J ;
RICE, PA ;
SHARFMAN, WH ;
SZNOL, M ;
URBA, WJ .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (04) :652-660
[7]   HER-2/neu protein: A target for antigen-specific immunotherapy of human cancer [J].
Disis, ML ;
Cheever, MA .
ADVANCES IN CANCER RESEARCH, VOL 71, 1997, 71 :343-371
[8]  
FEY MF, 1981, CANCER CLIN TRIALS, V4, P237
[9]  
KATSANIS E, 1994, BONE MARROW TRANSPL, V14, P563
[10]   OPTIMIZATION OF CULTURE CONDITIONS FOR ACTIVATION AND LARGE-SCALE EXPANSION OF HUMAN LYMPHOCYTES-T FOR BISPECIFIC ANTIBODY-DIRECTED CELLULAR IMMUNOTHERAPY [J].
LAMERS, CHJ ;
VANDEGRIEND, RJ ;
BRAAKMAN, E ;
RONTELTAP, CPM ;
BENARD, J ;
STOTER, G ;
GRATAMA, JW ;
BOLHUIS, RLH .
INTERNATIONAL JOURNAL OF CANCER, 1992, 51 (06) :973-979